Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.
Claire N HarrisonJacqueline S GarciaTim C P SomervailleJames M ForanSrdan VerstovsekCatriona JamiesonRuben A MesaEllen K RitchieSrinivas K TantravahiPankit VachhaniCasey L O'ConnellRami S KomrokjiJason HarbJessica E HuttiLeanne HolesAbdullah A MasudSilpa NuthalapatiJalaja PotluriNaveen PemmarajuPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
, improved TSS, hemoglobin response, and BMF. Further investigation is underway to qualify the potential for disease modification.